Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.04 USD

29.04
4,564,708

-0.05 (-0.17%)

Updated Sep 30, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

BioNTech (BNTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On BioNTech's (BNTX) third-quarter earnings call, investors will likely focus on the sales performance of its COVID-19 vaccine Comirnaty, developed in partnership with Pfizer.

Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales View

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q3 earnings and sales. It ups its sales and earnings view despite a decline in COVID-19 vaccine sales in Q3. Stock up in pre-market trading

Pre-Markets in Green to Start a Fresh Month

by Zacks Equity Research

Pre-Markets in Green to Start a Fresh Month

Mark Vickery headshot

Pre-Markets Up Ahead of New Fed Hike, Q3 Beats

by Mark Vickery

Big Pharma giants Pfizer (PFE) and Lilly (LLY) posted beats on both top and bottom lines this morning, while J&J (JNJ) is buying Abiomed (ABMD).

Pfizer (PFE) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 21.09% and 7.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Dow Notches Strongest Month of Trading Since 1976

by Mark Vickery

At +11%, it's the best October on record for the blue-chip index and the strongest single-month of trading since the U.S. Bicentennial.

Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More

by Zacks Equity Research

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

AbbVie (ABBV) Q3 Earnings Beat Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 2.81% and 0.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Shaun Pruitt headshot

Pfizer Earnings Preview: Growth & Diversification is Key

by Shaun Pruitt

Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.

Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y

by Zacks Equity Research

Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on sales numbers of Pfizer's (PFE) COVID-19 vaccine and COVID pill, Paxlovid.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $45.54 in the latest trading session, marking a +1.31% move from the prior day.

Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab

by Zacks Equity Research

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.

Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab

by Zacks Equity Research

Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.41% and 2.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $43.65, moving +1.84% from the previous trading session.

Derek Lewis headshot

These 3 Cash-Generating Machines Pay Investors Nicely

by Derek Lewis

In a historically-volatile year in the market so far in 2022, dividends have been a significant perk, helping to shield investors from drawdowns.

Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study

by Zacks Equity Research

Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.

Pfizer (PFE) Posts Positive Data on Bivalent BA.4/5 COVID Jab

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.